Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several serious diseases. The company is currently investigating the clinical effects of its most advanced drug candidate GS-248 in patients suffering from the autoimmune disease systemic sclerosis. Given positive study results, the company stands before a rapid broadening of its development programs toward additional indications.
Read more about our development projects.
Gesynta Pharma has a strong shareholder base including reputable specialist funds such as Industrifonden, Linc and Hadean Ventures, as well as a number of successful life science entrepreneurs. Under the leadership of a versatile management team with vast experience in efficient drug development processes, the company has been able to present positive study outcomes and generate a robust financial foundation for its continued value creation activities.
The members of Gesynta Pharma’s executive team hold considerable experience from leading positions in global pharmaceutical companies as well as in-depth knowledge in drug development, ranging from preclinical discovery projects to commercialization of approved drugs.
Gesynta Pharma’s board of directors has in-depth expertise in drug development and commercialization, vast experience from global strategic leadership positions, as well as access to extensive business and scientific networks in the life science industry.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our reputable board holds vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.
Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.